Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CODX vs BMRA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CODX Captures Overall Composite Edge (51.6 HOLD vs 44.5 HOLD), While BMRA Leads 3–2 on Growth & Valuation Pillars

CODX Overall Winner 6-Pillar Tally: CODX 2 – 3 BMRA (1 Tie) Matrix Metrics: CODX 5 – 4 BMRA

As of Nov 16, 2026, Co-Diagnostics, Inc. (CODX) captures the overall head-to-head institutional edge over Biomerica Inc (BMRA) on higher Unified Composite conviction (51.6/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples, Growth & Scale), while BMRA wins 3–2 across the 6-pillar growth and valuation breakdown. CODX trades at $0.23 (15.4x Forward P/E, -3415.8% operating margin) versus BMRA at $1.33 (N/M Forward P/E, -125.2% operating margin).

  • Growth vs. Quality Trade-Off: CODX earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD) and 2.92β · 148% Vol risk profile, whereas BMRA leads top-line expansion (-8.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CODX vs BMRA
CODX NASDAQ Head-to-Head Winner
Co-Diagnostics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.23
-12.26% 1D
Market Cap $2.3M
TTM Revenue $858,888
Forward P/E 15.4x
Beta / 30D Vol 2.92β · 148% Vol
Unified Composite Score
51.6 / 100 HOLD
Tech 55.0 Fund 54.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -31.1%), weak momentum, RSI 22
RSI-14: 21.7 · SMA20: $0.39 · SMA50: $0.78
BMRA NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap $6.0M
TTM Revenue $4.3M
Forward P/E N/M
Beta / 30D Vol 0.67β · 62% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.7%), weak momentum, RSI 28
RSI-14: 28.0 · SMA20: $1.62 · SMA50: $1.96

6-Pillar Scorecard Institutional Category Breakdown (CODX 2 – 3 BMRA)

Columns: Metric · CODX · BMRA
1. Valuation Multiples CODX
Forward P/E 15.4x N/M
Trailing P/E 15.4x N/M
PEG Ratio N/M N/M
EV / Revenue N/M 1.1x
2. Growth & Scale CODX
Revenue Growth (YoY) +94.6% -8.3%
Earnings Growth (YoY) +30.8% +0.0%
TTM Revenue (USD) $858,888 $4.3M
Market Cap $2.3M $6.0M
3. Profitability & Quality BMRA
Gross Margin 20.3% 0.9%
Operating Margin -3415.8% -125.2%
Net Profit Margin 0.0% -115.5%
Return on Equity (ROE) -192.8% -113.8%
4. Balance Sheet & Cash Flow BMRA
Cash Generation (TTM) -$28M EBITDA -$3.2M
Cash Flow Margin N/A -73.5%
Net Cash / Leverage $6.2M Net Cash $1.1M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BMRA
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 270.2% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CODX (5) vs BMRA (4)
Institutional Metric CODX BMRA Criterion Row Edge
Market Capitalization
Scale
$2.3M $6.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
15.4x N/M Lower Multiple CODX
Forward P/E Ratio
Valuation
15.4x N/M Lower Multiple CODX
Revenue Growth (YoY)
Growth
+94.6% -8.3% Higher Growth CODX
Operating Margin (TTM)
Profitability
-3415.8% -125.2% Higher Margin BMRA
Net Profit Margin
Profitability
0.0% -115.5% Higher Margin CODX
Return on Equity (ROE)
Capital Efficiency
-192.8% -113.8% Higher ROE BMRA
52-Week Range Position
Momentum
0% ($0–$14) 4% ($1–$3) Stronger Trend BMRA
Beta / 30D Volatility
Risk Regime
2.92β · 148% Vol 0.67β · 62% Vol Lower Realized Risk BMRA
Unified Institutional Score
Composite Signal
51.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite CODX
Trailing 12M Revenue (USD)
Operating Scale
$858,888 $4.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
20.3% 0.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$28M EBITDA ($6.2M Net Cash) -$3.2M ($1.1M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BMRA +37.12 pp
CODX: -65.31% · BMRA: -28.19%
3M Horizon BMRA +65.02 pp
CODX: -81.99% · BMRA: -16.97%
6M Horizon BMRA +42.48 pp
CODX: -83.44% · BMRA: -40.96%
1Y Horizon CODX +7.85 pp
CODX: -39.01% · BMRA: -46.86%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CODX Revenue BMRA Revenue CODX Op. Margin BMRA Op. Margin Margin Leader
FY2019 $0M $10M -2741.6% -46.4% BMRA
FY2020 $70M $10M 55.9% -41.0% CODX
FY2021 $100M $10M 47.1% -104.2% CODX
FY2022 $30M $20M -78.8% -24.0% BMRA
FY2023 $10M $10M -626.9% -135.3% BMRA
FY2024 $0M $10M -1023.7% -117.6% BMRA
FY2025 $0M $10M -8058.8% -96.7% BMRA
FY2026 N/A $0M N/A -119.5% BMRA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CODX BREAKDOWN
173d in phase · OBV DISTRIBUTION
Current IV 270.2%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact CODX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BMRA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BMRA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CODX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.3M market capitalization and -3415.8% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BMRA Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $6.0M market capitalization and -125.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CODX vs BMRA Key Questions & Quantitative Answers

As of Nov 16, 2026, Co-Diagnostics, Inc. (CODX) captures the overall head-to-head institutional edge over Biomerica Inc (BMRA) on higher Unified Composite conviction (51.6/100 HOLD vs. 44.5/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples, Growth & Scale), while BMRA wins 3–2 across the 6-pillar growth and valuation breakdown. CODX trades at $0.23 (15.4x Forward P/E, -3415.8% operating margin) versus BMRA at $1.33 (N/M Forward P/E, -125.2% operating margin). Growth vs. Quality Trade-Off: CODX earns the overall head-to-head edge with a stronger Unified Composite Score (51.6/100 HOLD vs. BMRA 44.5/100 HOLD) and 2.92β · 148% Vol risk profile, whereas BMRA leads top-line expansion (-8.3% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: CODX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.7); meanwhile BMRA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CODX leads the Growth & Scale pillar: CODX posts +94.6% YoY revenue growth and +30.8% YoY earnings growth on $858,888 TTM revenue (20.3% gross margin, -3415.8% operating margin), compared with BMRA at -8.3% YoY revenue growth and +0.0% YoY earnings growth on $4.3M TTM revenue (0.9% gross margin, -125.2% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), CODX cumulative revenue shifted -85.7% while BMRA shifted +0.0%. In operating R&D and SG&A reinvestment, CODX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BMRA.

CODX screens cheaper on headline valuation multiples. CODX trades at 15.4x Forward P/E, 15.4x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas BMRA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CODX (-192.8% ROE) versus BMRA (-113.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CODX carries 270.2% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.92β · 148% Vol realized risk). By comparison, BMRA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 62% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.